PLEASANTON, Calif. , May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and disputes between the two companies. As part of the settlement, 10x expects that Bruker will pay $68 million in equal quarterly installments... Read More

PLEASANTON, Calif. , May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million , a 2% decrease from the corresponding period of 2024, primarily... Read More

PLEASANTON, Calif. , April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13 , at 11:20 a.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's... Read More

PLEASANTON, Calif. , April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025 . The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss... Read More

10x Genomics' ATAC-Seq patents found valid and infringed PLEASANTON, Calif. , March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025 , in the United States District Court for the District of Delaware , Parse agreed - a week before trial was to start... Read More

New single cell and spatial innovations extend 10x Genomics' technology and performance leadership across all three platforms PLEASANTON, Calif. , Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new product innovations to solidify its position as the best partner for... Read More

PLEASANTON, Calif. , Feb. 18, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4 , at 11:10 a.m. Eastern Time . Interested parties may access a live webcast of the fireside chat on the "Investors" section of the... Read More

PLEASANTON, Calif. , Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding... Read More

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance researchers' understanding of cellular behavior and gene function REDWOOD CITY, Calif. , Feb. 6, 2025 /PRNewswire/ -- Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an... Read More

PLEASANTON, Calif. , Jan. 28, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced it will report financial results for the fourth quarter and full year ended December 31, 2024 after market close on Wednesday, February 12, 2025 . The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m.... Read More

PLEASANTON, Calif. , Jan. 2, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13 , at 7:30 a.m. Pacific Time Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at:... Read More

PLEASANTON, Calif. , Nov. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Wolfe Research 2024 Healthcare Conference on Tuesday, November 19 , at 1:00 p.m. Eastern Time . Interested parties may access a live webcast of the fireside chat on the "Investors" section of the... Read More

Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS and PLEASANTON, Calif. , Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics' Visium HD as part of its pioneering work to understand the unique biology of exceptional cancer survivors, whose... Read More

PLEASANTON, Calif. , Oct. 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Revenue was $151.7 million for the third quarter, in line with the company's preliminary announcement, a 1% decrease over the corresponding period of 2023, primarily driven by lower instrument... Read More

PLEASANTON, Calif. , Oct. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of two new Chromium products intended to democratize access to single cell analysis. The new offerings – GEM-X Flex and GEM-X Universal Multiplex – introduce significant improvements in performance, workflow and cost effectiveness, enabling more researchers to pursue... Read More

PLEASANTON, Calif. , Oct. 9, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary select results for the third quarter ended September 30, 2024 . Preliminary Select Third Quarter 2024 Results Revenue of approximately $151.7 million for the third quarter ended September 30, 2024 , representing an approximate 1% decrease from the corresponding prior... Read More

PLEASANTON, Calif. , Oct. 1, 2024 /PRNewswire/ -- At the Human Cell Atlas General Meeting held September 29-30 in Milan, Italy , 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, shared new details about its upcoming product roadmap and its ongoing strategy to democratize access to single cell analysis. During its Foundational Sponsor talk in the Sept. 29 Technology Showcase, 10x Genomics... Read More

In the September 9 cover article of Cancer Cell , researchers integrated 10x single cell and spatial technologies to identify a mechanism of glioblastoma recurrence in mice and develop a promising potential therapeutic approach. PLEASANTON, Calif. , Sept. 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Chromium Single Cell Gene Expression and... Read More

PLEASANTON, Calif. , Sept. 3, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of Chromium Xo, a new addition to its fleet of Chromium single cell instruments. Designed to meet the needs of researchers who desire high-quality data on limited budgets, Chromium Xo offers an affordable entry point into routine, high-performance single cell analysis.... Read More

PLEASANTON, Calif. , Aug. 22, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4 , at 10:45 a.m. Eastern Time . Interested parties may access a live webcast of the fireside chat on the "Investors"... Read More

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1 . In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions. Justin... Read More

PLEASANTON, Calif. , Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Revenue was $153.1 million for the second quarter, a 4% increase over the corresponding period of 2023, primarily driven by stronger contributions from consumables. Began shipping Xenium Prime 5K , which... Read More

Garvan Institute's TenK10K Project Aims to Map 50 Million Human Cells from 10,000 People PLEASANTON, Calif. , Aug. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today its involvement in TenK10K, a large-scale, multi-year study led by the Garvan Institute of Medical Research. The TenK10K project intends to map 50 million human cells from 10,000 people to... Read More

PLEASANTON, Calif. , July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the second quarter ended June 30, 2024 after market close on Thursday, August 8, 2024 . The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time... Read More

Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif. , June 27, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its Xenium In Situ platform was used in a study published in the Journal of Dental Research, offering novel insights into... Read More

New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping its new Xenium Prime 5K Pan-Tissue and Pathways panel. The new panel features an enhanced chemistry to increase plex by an order of... Read More

New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , May 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of... Read More

PLEASANTON, Calif. , May 2, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14 , at 4:20 p.m. Pacific Time . Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's... Read More

PLEASANTON, Calif. , April 30, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue. Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome... Read More

PLEASANTON, Calif. , April 10, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the first quarter ended March 31, 2024 after market close on Tuesday, April 30, 2024 . The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time... Read More

Began global shipments for Visium HD, a new product that enables whole transcriptome spatial discovery at single cell–scale resolution PLEASANTON, Calif. , March 26, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Visium HD... Read More

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif. , March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit... Read More

The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif. , March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression... Read More

PLEASANTON, Calif. , Feb. 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the 44 th Annual TD Cowen Health Care Conference on Tuesday, March 5 , at 2:50 p.m. Eastern Time . Interested parties may access a live webcast of the fireside chat on the "Investors" section of the... Read More

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif. , Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024. Recent Highlights Revenue was $184.0 million for the fourth quarter... Read More

GEM-X, the next generation of the company's leading single cell technology architecture, enables higher performance at larger scale and lower cost Pre-orders now open for first two Chromium products powered by GEM-X; expected to ship in Q1 PLEASANTON, Calif. , Feb. 7, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of GEM-X , the next generation... Read More

New single cell and spatial products set to deliver higher performance, improve ease of use and enable researchers to measure more biology PLEASANTON, Calif. , Feb. 5, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a series of new products and technology demonstrations that will be presented at the 2024 Advances in Genome Biology and Technology (AGBT)... Read More

PLEASANTON, Calif. , Jan. 24, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after market close on Thursday, February 15, 2024 . The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time /... Read More

PLEASANTON, Calif. , Jan. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select results for the fourth quarter and full year ended December 31, 2023 . Preliminary, Unaudited Select Fourth Quarter 2023 Financial Results Revenue of approximately $184.0 million for the three months ended December 31, 2023 , representing 18% growth... Read More

PLEASANTON, Calif. , Dec. 21, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 , at 9:00 a.m. Pacific Time . Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at:... Read More

Founding Network Members Will Accelerate Access to Proof-of-Concept Data for Prospective Xenium Customers Worldwide PLEASANTON, Calif. , Dec. 20, 2023 /PRNewswire/ -- 10x Genomics, Inc. , (Nasdaq: TXG), a leader in single cell and spatial biology, today announced the launch of its Xenium Catalyst Network, a global group of technically qualified research institutions that will accelerate access to Xenium proof-of-concept data... Read More

A team of 10x Genomics scientists conducted a comprehensive analysis of human breast tumor microenvironments using all three of its industry-leading platforms PLEASANTON, Calif. , Dec. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that Nature Communications has published a 10x-conducted study using the Chromium Single Cell, Visium Spatial and Xenium In... Read More

Xenium In Situ demonstrates higher transcript counts per gene in new comparison study of three spatial imaging platforms PLEASANTON, Calif. , Dec. 13, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a new non-peer-reviewed study has independently evaluated the technical performance of three spatial imaging platforms and found the Xenium In Situ platform... Read More

PLEASANTON, Calif. , Dec. 7, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today a collaboration with the NIH Intramural Center for Alzheimer's and Related Dementias (NIH CARD) to build a more comprehensive single cell atlas of the human brain to further neuroscience research. Known for complementing a broad range of NIH-funded research that requires harnessing... Read More

Jury Awards 10x Genomics Over $31 Million in Damages and Finds All Seven Asserted Patents Valid and Willfully Infringed by NanoString GeoMx Decision is Third Ruling Against NanoString, Showing Serial Infringement of 10x Patents PLEASANTON, Calif. , Nov. 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that a jury in the U.S. District Court for the... Read More

PLEASANTON, Calif. and PARIS , Nov. 6, 2023 /PRNewswire/ -- OWKIN and 10x Genomics, Inc. (Nasdaq: TXG), announce they have entered into an agreement to add 10x Genomics spatial omics and single-cell technologies to the ambitious MOSAIC project, which has already garnered attention for its pioneering work in tumor analysis for therapeutic discovery. Unveiled in June 2023 , MOSAIC is a landmark $50 million project that... Read More

PLEASANTON, Calif. , Nov. 2, 2023 /PRNewswire/ -- 10x Genomics, Inc . (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Revenue was $153.6 million for the third quarter, a 17% increase over the corresponding period of 2022, driven by Xenium momentum. Advanced Xenium gene panel strategy, launching new targeted and... Read More

PLEASANTON, Calif. , Nov. 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Stephens 25 th Annual Conference on Tuesday, November 14 , at 10:00 a.m. Central Time . Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's... Read More

Scientific pre-print featuring customer-generated data demonstrates the power of single cell spatial analysis to more directly assess unique tissue microenvironments and cell-cell interactions PLEASANTON, Calif. , Oct. 26, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the 10x Xenium Analyzer was used in a study recently published on bioRxiv... Read More

PLEASANTON, Calif. , Oct. 11, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the third quarter 2023 after market close on Thursday, November 2, 2023 . The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results,... Read More

UPC Denies Second Preliminary Injunction Request; Prior Injunctions Against NanoString's CosMx Products in Europe Remain in Full Effect PLEASANTON, Calif. , Oct. 10, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") has declined to issue a second preliminary injunction against NanoString Technologies, Inc.... Read More

Second Injunction Issued Against CosMx PLEASANTON, Calif. , Sept. 19, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that the European Unified Patent Court ("UPC") issued a preliminary injunction against NanoString Technologies, Inc. (Nasdaq: NSTG ) for infringing European Patent 4 108 782 B1 ("the EP 782 patent," docket No 459746/2023). The preliminary... Read More

Strengthen cellular analysis with cost-efficient multiomic readouts and streamlined workflows PLEASANTON, Calif. , Sept. 14, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new kit to expand the capabilities of its Chromium Single Cell Gene Expression Flex assay to include high-throughput multiomic cellular profiling. The new... Read More

Researchers uncover mechanisms behind divergent responses to immune checkpoint blockade between primary and metastatic brain tumors PLEASANTON, Calif. , Sept. 5, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its technologies were used in a study published in the Journal of Clinical Investigation to explain why immune checkpoint blockade, a type of... Read More

PLEASANTON, Calif. , Aug. 30, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the Morgan Stanley 21 st Annual Global Healthcare Conference on Tuesday, September 12 , at 8:50 a.m. Eastern Time . Interested parties may access a live webcast of the fireside chat on the "Investors"... Read More

Rapid growth and adoption of Xenium Analyzer demonstrates strength of company's innovation engine, broad commercial reach and operational scale PLEASANTON, Calif. , Aug. 29, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has shipped more than 100 Xenium Analyzer instruments in the eight months since the platform's launch. The milestone reflects... Read More

PLEASANTON, Calif. , Aug. 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the second quarter ended June 30, 2023. Recent Highlights Revenue was $146.8 million for the second quarter, representing a 28% increase over the corresponding period of 2022. Accelerated Xenium's momentum with strong shipments, multiple new curated and... Read More

PLEASANTON, Calif. , July 13, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it will report financial results for the second quarter 2023 after market close on Thursday, August 3, 2023 . The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business... Read More

Data Uncovers New Gene Signature to Help Understand Persistence in CAR T-cells PLEASANTON, Calif. , July 5, 2023 /PRNewswire/ -- 10x Genomics , Inc . (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that its single-cell genomic technologies were used in a study published in the journal Nature Medicine about new gene signatures that explain why some children with leukemia have longer remission after... Read More

Also Files New Suit Against Vizgen's MERSCOPE Products for Patent Infringement PLEASANTON, Calif. , June 1, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it filed new patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and Vizgen, Inc. in the European Unified Patent Court. 10x Genomics' new lawsuits allege that the use and... Read More

Combining tissue profiling with whole transcriptome spatial analysis and high-plex protein co-detection enables a deeper, more holistic understanding of tissue organization PLEASANTON, Calif. , May 24, 2023 /PRNewswire/ -- 10x Genomics , Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of a new Visium CytAssist Gene and Protein Expression product to expand the... Read More

10x Genomics is seeking additional injunctions to protect its intellectual property PLEASANTON, Calif. , May 17, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has won an injunction in its patent litigation against NanoString Technologies, Inc. (Nasdaq: NSTG) and NanoString Technologies Germany GmbH. The Munich Regional Court issued a permanent... Read More

PLEASANTON, Calif. , May 3, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Revenue was $134.3 million for the first quarter, representing a 17% increase over the corresponding period of 2022. Surpassed 5,000 customer publications using 10x Genomics products, demonstrating the impact of single cell and spatial technologies to... Read More

PLEASANTON, Calif. , April 25, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2023 Healthcare Conference on Wednesday, May 10 , at 2:20 p.m. Pacific Time . Interested parties may access a live webcast of the fireside chat on the... Read More

PLEASANTON, Calif. , April 12, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced it will report financial results for the first quarter 2023 after market close on Wednesday, May 3, 2023 . The company will host a conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to... Read More

PLEASANTON, Calif. , Feb. 22, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming 43 rd Annual Cowen Healthcare Conference in Boston, Massachusetts . 10x Genomics' management is scheduled to participate in a fireside chat on Monday, March 6 , at 11:10 a.m. Eastern Time . Interested... Read More

Q4 2022 revenue growth of 9% and FY 2022 revenue growth of 5% over the corresponding periods of 2021 PLEASANTON, Calif. , Feb. 15, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG) today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided outlook for 2023. Recent Highlights Revenue was $156.2 million for the fourth quarter and $516.4 million for the full year of 2022,... Read More

Showcases unique power and scalability of Chromium Flex across fresh, frozen and FFPE samples, including data from an 8 million cell experiment on a single run Reinforces performance advantages of Visium CytAssist for unbiased spatial discovery with new data and an exclusive product pipeline, including Visium HD Shares technology roadmap for the Xenium platform, including a broader menu of targeted and customizable panels... Read More

PLEASANTON, Calif. , Jan. 19, 2023 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG) today announced it will report financial results for the fourth quarter and full year ended December 31, 2022 after market close on Wednesday, February 15, 2023 . The company's management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and... Read More

PLEASANTON, Calif. , Dec. 28, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the company will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California . 10x Genomics' management is scheduled to present on Monday, January 9 , at 7:30 a.m. Pacific Time . Management is also... Read More

Began global shipments of Xenium Analyzer, the highest throughput instrument for subcellular In Situ profiling PLEASANTON, Calif. , Dec. 8, 2022 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced the first commercial shipments of its Xenium platform for in situ analysis. Xenium is the next generation of targeted spatial profiling of... Read More